Meeting
2014 ASCO Annual Meeting
Strategic 1-multi-line therapy trial in unresectable wild-type RAS metastatic colorectal cancer: A gercor randomized open-label phase III study.
Authors
Benoist Chibaudel
Hôpital Saint-Antoine, Paris, France
Benoist Chibaudel , Christophe Tournigand , Franck Bonnetain , Marine Hug de larauze , Armand De Gramont , Pierre Laurent-Puig , Christophe Louvet , Thierry André , Aimery De Gramont
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT01910610
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS3648^)
DOI
10.1200/jco.2014.32.15_suppl.tps3648
Abstract #
TPS3648^
Poster Bd #
111A
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Efficacy of cetuximab immediately after bevacizumab: A phase III multicenter trial comparing two different sequences of cetuximab and FOLFOX in K-Ras WT metastatic colorectal cancer patients refractory FOLFIRI/bevacizumab.
First Author: Stefano Cascinu
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAF V600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 ASCO Annual Meeting
BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz